Ascendis Pharma A/S released 52-week data from its ApproaCH trial, showing that TransCon CNP (navepegritide) improved growth and bone...

Connect Biopharma has initiated its Phase 2 Seabreeze STAT Asthma study to evaluate rademikibart’s safety and efficacy as an...

Revive Therapeutics is partnering with Defence R&D Canada (DRDC) to study Bucillamine as a potential treatment for nerve agent...

Ascendis Pharma A/S released 214-week data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults...

Galectin Therapeutics announced positive results from its NAVIGATE trial of belapectin, a galectin-3 inhibitor, for patients with MASH cirrhosis...

Quantum BioPharma has completed the 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis (MS) drug, Lucid-21-302 (Lucid-MS)....

Medera Inc., a clinical-stage biopharmaceutical company, announced that data from its Phase 1/2a MUSIC-HFpEF clinical trial investigating its gene...

Alterity Therapeutics presented data at the 2025 International MSA Congress, highlighting positive Phase 2 results for their drug ATH434...

In this interview, Rachael Thomas Higgins, Chief Commercial Officer of PicnicHealth, offers her perspective on the pivotal role of...

Cognition Therapeutics presented preclinical data at ARVO demonstrating the potential of zervimesine (CT1812) to protect retinal cells from damage...